What is claimed is:

1. A pharmaceutical composition for oral administration of fenofibrate comprising:

a) a therapeutically effective amount of fenofibrate; and

b) a solubilizer comprising a vitamin E substance, a trialkyl citrate, a lactone, a nitrogen-containing solvent or combination thereof.

2. The pharmaceutical composition of claim 1, wherein said solubilizer is a vitamin E substance.

3. The pharmaceutical composition of claim 2, wherein said vitamin E substance is selected from the group consisting of tocopherols, tocopherol derivatives with organic acids, tocotrienols and mixtures thereof.

4. The pharmaceutical composition of claim 3, wherein said vitamin E substance is selected from the group consisting of alpha tocopherol, alpha tocopheryl acetate, alpha tocopheryl acid succinate, alpha tocopherol polyethylene glycol 1000 succinate and mixtures thereof.

5. The pharmaceutical composition of claim 1, wherein said solubilizer is a trialkyl citrate.

6. The pharmaceutical composition of claim 5, wherein said trialkyl citrate is selected from the group consisting of triethyl citrate, acetyltriethyl citrate, tributyl citrate, acetyltributyl citrate and mixtures thereof.

7. The pharmaceutical composition of claim 6, wherein said trialkyl citrate is triethyl citrate.

8. The pharmaceutical composition of claim 1, wherein said solubilizer is a lactone.

9. The pharmaceutical composition of claim 8, wherein said lactone is selected from the group consisting of ε-caprolactone and isomers thereof, δ-valerolactone and isomers thereof and β-butyrolactone and isomers thereof and mixtures thereof.

10. The pharmaceutical composition of claim 1, wherein said solubilizer is a nitrogen-containing solvent.

11. The pharmaceutical composition of claim 10, wherein said nitrogen-containing solvent is selected from the group consisting of dimethylformamide, dimethylacetamide, N-alkylpyrrolidone, N-hydroxyalkylpyrrolidone, N-alkylpiperidone, N-alkylcaprolactam and mixtures thereof.

12. The pharmaceutical composition of claim 10, wherein said solubilizer is selected from the group consisting of N-methyl 2-pyrrolidone, N-ethyl 2-pyrrolidone and mixtures thereof.

13. A pharmaceutical composition for oral administration of fenofibrate comprising:

a) a therapeutically effective amount of fenofibrate; and

b) a solubilizer comprising a phospholipid.

14. The pharmaceutical composition of claim 13, wherein said phospholipid is selected from the group consisting of phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidic acid, lecithin, lysolecithin, lysophospholipids or a mixture thereof.

15. A pharmaceutical composition for oral administration of fenofibrate comprising:

a) a therapeutically effective amount of fenofibrate; and

b) a solubilizer comprising a glycerol acetate, an acetylated glycerol fatty acid ester or combination thereof.

16. The pharmaceutical composition of claim 15, wherein said glycerol acetate is selected from the group consisting of acetin, diacetin, triacetin and mixtures thereof.

17. The pharmaceutical composition of claim 16, wherein said glycerol acetate is triacetin.

18. The pharmaceutical composition of claim 15, wherein said acetylated glycerol fatty acid ester is selected from the group consisting of acetylated monoglycerides, acetylated diglycerides and mixtures thereof.

19. The pharmaceutical composition of claim 18, wherein the glycerol fatty acid ester is an acetylated monoglyceride.

20. The pharmaceutical composition of claim 18, wherein said acetylated glycerol fatty acid ester is distilled acetylated monoglyceride.

21. A pharmaceutical composition for oral administration of fenofibrate comprising:

a) a therapeutically effective amount of fenofibrate; and

b) a solubilizer comprising a lower alcohol fatty acid ester.

22. The pharmaceutical composition of claim 21, wherein said lower alcohol fatty acid ester comprises a lower alcohol moiety and a fatty acid moiety wherein the fatty acid moiety includes about 6-22 carbon atoms and the lower alcohol moiety includes about 2-4 carbon atoms.

23. The pharmaceutical composition of claim 22, wherein said lower alcohol fatty acid ester is selected from the group consisting of ethyl oleate, ethyl linoleate, ethyl caprylate, ethyl caprate, isopropyl myristate, isopropyl palmitate and mixtures thereof.

24. A pharmaceutical composition for oral administration of fenofibrate comprising:

a) a therapeutically effective amount of fenofibrate; and

b) a solubilizer consisting essentially of a non-acetylated glycerol fatty acid ester.

25. The pharmaceutical composition of claim 24, wherein said non-acetylated glycerol fatty acid ester is selected from the group of monoglycerides, diglycerides, triglycerides or a mixture thereof.

26. A pharmaceutical composition for oral administration of fenofibrate comprising:

a) a therapeutically effective amount of fenofibrate; and

b) a solubilizer consisting essentially of a propylene glycol ester.

27. The pharmaceutical composition of claim 26, wherein said propylene glycol ester is selected from the group consisting of propylene carbonate, propylene glycol monoacetate, propylene glycol diacetate, propylene glycol fatty acid esters, acetylated propylene glycol fatty acid esters and mixtures thereof.

28. The pharmaceutical composition of claim 26, wherein said propylene glycol ester is selected from the group consisting of propylene glycol fatty acid monoesters, propylene glycol fatty acid diesters, and mixtures thereof.

29. The pharmaceutical composition of claim 26, wherein said propylene glycol ester is propylene glycol monocaprylate.

30. The pharmaceutical composition of claim 26, wherein said propylene glycol ester is selected from the group of propylene glycol dicaprylate, propylene glycol dicaprate, propylene glycol dicaprylate/dicaprate and mixtures thereof.

31. A pharmaceutical composition for oral administration of fenofibrate comprising:

a) a therapeutically effective amount of fenofibrate; and

b) a solubilizer consisting essentially of an ethylene glycol ester.

32. The pharmaceutical composition of claim 31, wherein said ethylene glycol ester is selected from the group consisting of monoethylene glycol monoacetates, diethylene glycol esters, polyethylene glycol esters and mixtures thereof.

33. The pharmaceutical composition of claim 31, wherein said ethylene glycol ester is selected from the group consisting of ethylene glycol monoacetates, ethylene glycol diacetates, ethylene glycol fatty acid monoesters, ethylene glycol fatty acid diesters and mixtures thereof.

34. The pharmaceutical composition of claim 31, wherein said ethylene glycol ester is selected from the group consisting of polyethylene glycol fatty acid monoesters, polyethylene glycol fatty acid diesters and mixtures thereof.

35. The pharmaceutical composition of claim 31, wherein said ethylene glycol ester is a transesterification product of polyethylene glycol and a vegetable oil or triglyceride.

36. A pharmaceutical composition for oral administration of fenofibrate comprising:

(a) a therapeutically effective amount of fenofibrate; and

(b) solubilizer consisting essentially of glycerol fatty acid ester, a propylene glycol ester, an ethylene glycol ester, a lower alcohol fatty acid ester or a ~~mixture thereof.~~

37. The pharmaceutical composition of any one of claims 1, 13, 15, 21, 24, 26, 31 or 36, in a liquid form.

38. The pharmaceutical composition of any one of claims 1, 13, 15, 21, 24, 26, 31 or 36, in a semi-liquid form.

39. The pharmaceutical composition of any one of claims 1, 13, 15, 21, 24, 26, 31 or 36, wherein the fenofibrate is at least 50% solubilized in said composition.

40. The pharmaceutical composition of any one of claims 1, 13, 15, 21, 24, 26, 31 or 36, wherein the fenofibrate is at least 75% solubilized in said composition.

41. A pharmaceutical dosage form comprising the pharmaceutical composition of any one of claims 1, 13, 15, 21, 24, 26, 31 or 36.

42. The pharmaceutical dosage form of claim 41, wherein fenofibrate is present in an amount of from about 40 to about 250 mg.

43. The pharmaceutical dosage form of claim 42, wherein fenofibrate is present in an amount of from about 67 to about 200 mg.

44. The pharmaceutical dosage form of claim 41, in capsule form.

45. The pharmaceutical dosage form of claim 41, in the form of a drink.

46. The pharmaceutical composition of any one of claims 1, 13, 15, 21, 24, 26, 31 or 36, wherein the fenofibrate is completely solubilized in said composition.

47. The pharmaceutical dosage form of claim 42, wherein fenofibrate is solubilized in an amount of at least about 40 mg.

48. The pharmaceutical dosage form of claim 42, wherein fenofibrate is solubilized in an amount of at least about 67 mg.

49. The pharmaceutical dosage form of claim 42, wherein fenofibrate is solubilized in an amount of at least about 100 mg.

50. A pharmaceutical composition for administration of a hydrophobic drug comprising:

(a) a therapeutically effective amount of a hydrophobic drug; and

(b) a vitamin E substance,

wherein the hydrophobic drug is present in an amount of from about 0.1 to 30 % w/w of the composition and is at least about 50 % solubilized in the composition, and wherein the vitamin E substance is present in an amount of from about 1 to 99 % w/w of said composition.

51. A method for treating a patient who would benefit from administration of a fenofibrate-containing composition comprising administering to the patient a therapeutically acceptable amount of any one of claims 1, 13, 15, 21, 24, 26, 31 or 36.